Deucravacitinib Improved Interstitial Pneumonia Along with KL-6 Reduction in a Patient with Psoriasis: A Case Report
Abstract
Abstract This case report describes a patient with psoriasis and interstitial pneumonia (IP) presenting with linear opacities who was treated with deucravacitinib, aiming to highlight the potential role of deucravacitinib in improving IP. Psoriasis is a chronic immune-mediated skin disease involving T helper (Th) 17 cells, often accompanied by systemic comorbidities. Deucravacitinib, a selective oral tyrosine kinase 2 (TYK2) inhibitor targeting interleukin (IL)-23 and type I interferons, has shown strong efficacy and safety in psoriasis treatment. Interstitial pneumonia (IP) is a group of lung diseases characterized by inflammation, fibrosis, and progressive respiratory decline. Cytokines play key roles in its pathogenesis. Emerging evidence suggests that psoriasis has higher risks of IP, possibly due to shared IL-23/IL-17 pathway. The patient showed marked improvement in skin and lung findings, along with KL-6 levels after deucravacitinib treatment. TYK2 mediates downstream signaling of key pro-fibrotic and pro-inflammatory cytokines involved in IP. Therefore, we consider that deucravacitinib may have contributed to the improvement of IP by blocking these signaling pathways, thereby suppressing chronic T cell–driven inflammation and fibrosis. Further accumulation of cases and continued research will be essential in advancing discussions on the clinical utility of TYK2 inhibitors in IP management.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.